Panitumumab a novel drug in cancer treatment.
Ann Oncol
; 18 Suppl 6: vi16-21, 2007 Jun.
Article
in En
| MEDLINE
| ID: mdl-17591813
ABSTRACT
The epidermal growth factor receptor (EGFR) is a member of the erbB family overexpressed in most of the solid tumors. In cancer cells, the overexpression of EGFR correlates with the development and the progression of tumor. Panitumumab is a fully human monoclonal antibody that blocks the extracellular domain of the EGFR and has not been associated with the formation of any antibodies directed against it. This review summarizes on the preclinical and clinical development of panitumumab in human solid tumors. As bevacizumab and cetuximab have been approved for colorectal cancer because of their improvements in progression-free survival and overall survival when associated with chemotherapy, panitumumab represents an interesting molecule which needs more phase III studies to validate its efficacy.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Colorectal Neoplasms
/
Antibodies, Monoclonal
/
Antineoplastic Agents
Limits:
Animals
/
Humans
Language:
En
Journal:
Ann Oncol
Journal subject:
NEOPLASIAS
Year:
2007
Document type:
Article
Affiliation country:
Italia